Welcome to our dedicated page for Inhibrx Biosciences news (Ticker: INBX), a resource for investors and traders seeking the latest updates and insights on Inhibrx Biosciences stock.
Inhibrx Biosciences, Inc. reports clinical and corporate updates for a pipeline of biologic therapeutic candidates developed with protein engineering platforms. The company’s programs include ozekibart (INBRX-109), a tetravalent death receptor 5 agonist antibody studied in oncology indications including chondrosarcoma, colorectal cancer and Ewing sarcoma, and INBRX-106, a hexavalent OX40 agonist evaluated in immuno-oncology settings such as head and neck squamous cell carcinoma.
Company developments commonly cover clinical trial data, regulatory submissions and designations, scientific conference presentations, quarterly and annual financial results, and capital resources. Inhibrx Biosciences also carries a completed corporate history tied to its 2024 separation from Inhibrx, Inc. following the sale of the INBRX-101 program.
Inhibrx (Nasdaq: INBX) reported fourth quarter and fiscal 2025 results on March 19, 2026, highlighting clinical milestones and financials. Cash and cash equivalents were $124.2 million as of December 31, 2025, and the company obtained $75.0 million in loan proceeds on March 18, 2026.
Fiscal 2025 R&D expense was $113.0 million versus $203.7 million in 2024; net loss was $140.1 million for fiscal 2025 versus net income of $1.7 billion in fiscal 2024. Key clinical milestones and trial data readouts are scheduled across 2026, including a planned BLA submission early Q2 2026 for ozekibart.
Inhibrx (Nasdaq: INBX) will present clinical data at the ESMO Sarcoma and Rare Cancers Congress in Lugano, Switzerland, March 12-14, 2026. A mini oral session on March 12 will feature the Phase 1 study of tetravalent DR5 agonist ozekibart (INBRX-109) combined with irinotecan and temozolomide in adolescents and adults with Ewing sarcoma.
Lead author is Rashmi Chugh, M.D.; presenting author is Ana Sebio, M.D., Ph.D. The presentation (abstract 84MO) is scheduled for March 12 at 11:30 am CET in Hall A, Palazzo dei Congressi Lugano, and will be accessible via a link on the company investor website upon commencement.
Inhibrx (Nasdaq: INBX) provided clinical updates on INBRX-106 and ozekibart (INBRX-109) on December 16, 2025. Key progress: INBRX-106 has enrolled 46 of 60 randomized patients in the Phase 2 portion for first-line unresectable/metastatic HNSCC and expects to finish Phase 2 enrollment in Q1 2026. A separate Phase 1/2 checkpoint inhibitor refractory/relapsed NSCLC cohort completed enrollment at 34 patients in November 2025. Current datasets lack maturity to support conclusions; maturity expected in 2H 2026 to inform efficacy versus standard of care.
Ozekibart (INBRX-109) completed enrollment of 44 patients in the FOLFIRI expansion (late-line colorectal cancer); PFS data expected to be mature in Q2 2026. Enrollment for the IRI/TMZ Ewing sarcoma cohort is expected to complete in Q2 2026; if response trends persist, Inhibrx plans an FDA meeting in 2H 2026 to discuss accelerated approval.
Inhibrx (Nasdaq: INBX) reported third quarter 2025 results and clinical updates on November 14, 2025. Ozekibart (INBRX-109) met the registrational trial primary endpoint in chondrosarcoma with a statistically significant improvement in median progression-free survival versus placebo; key secondaries showed improved disease control and quality of life. The company plans to submit a BLA in Q2 2026. Interim expansion-cohort data show high response and disease control rates in colorectal cancer and Ewing sarcoma.
Financials: cash and cash equivalents were $153.1M as of September 30, 2025 (down from $186.6M on June 30, 2025). R&D expense was $28.5M and G&A was $5.3M for Q3 2025. Net loss was $35.3M or $2.28 per share.
Inhibrx (Nasdaq: INBX) announced presentations and a poster at three upcoming scientific conferences in November 2025 covering clinical and preclinical data for the DR5 agonist ozekibart (INBRX-109) and related DR5 clinical results.
Events and highlights:
- Nov 5, 2025 — La Jolla: DR5 agonist clinical data presentation by Josep Garcia, PhD and Katelyn Willis, PhD.
- Nov 14, 2025 — Boca Raton (CTOS): Phase 2 ChonDRAgon randomized registrational results in conventional chondrosarcoma (lead author Robin L. Jones, MD).
- Nov 22, 2025 — Honolulu (SNO): Poster on INBRX-109 anti-tumor activity in GBM models, monotherapy and with TMZ.
Inhibrx (Nasdaq: INBX) reported positive topline results from the registrational ChonDRAgon study of ozekibart (INBRX-109) in advanced/metastatic chondrosarcoma and provided interim expansion-cohort updates in colorectal cancer and Ewing sarcoma.
Key results: PFS HR 0.479 (P<0.0001), median PFS 5.52 vs 2.66 months; disease control rate 54% vs 27.5%. CRC combo (FOLFIRI) interim: ORR 23%, DCR 92% (26 evaluable). Ewing combo (IRI/TMZ) interim: ORR 64%, DCR 92% (25 evaluable). One early hepatotoxicity-related fatality occurred; hepatic AEs 11.8% vs 4.5% placebo. Company plans a BLA filing in Q2 2026.
Inhibrx (Nasdaq: INBX) will webcast topline results from the registrational ChonDRAgon study of ozekibart (INBRX-109) versus placebo in advanced/metastatic unresectable chondrosarcoma on Thursday, October 23, 2025 at 1:30 p.m. PT.
The company will also provide updates on two expansion cohorts: ozekibart plus FOLFIRI in late-line colorectal cancer and ozekibart with irinotecan and temozolomide in refractory Ewing sarcoma. Investors can join via webcast or listen by dial-in; the webcast will be available for 60 days after the event and the corporate presentation will be updated in the Investors section of the company website.
Inhibrx (NASDAQ:INBX) reported Q2 2025 financial results following its spin-off from Former Parent and the $2.0B INBRX-101 sale to Sanofi in May 2024. The company ended Q2 with $186.6 million in cash, down from $216.5M in Q1. Revenue was $1.3 million, up from $0.1M in Q2 2024.
R&D expenses decreased to $22.3 million from $67.6M, while G&A expenses dropped to $6.4 million from $93.4M. The company reported a net loss of $28.7 million ($1.85 per share) compared to net income of $1.9B in Q2 2024. Two key clinical trials are progressing with data readouts expected in late 2025: the ozekibart Phase 2 trial for chondrosarcoma and INBRX-106 Phase 2/3 trial for head and neck cancer.
Inhibrx (NASDAQ: INBX) reported its Q1 2025 financial results, showing a net loss of $43.3 million ($2.80 per share), an improvement from the $78.7 million loss in Q1 2024. The company's cash position strengthened to $216.5 million, up from $152.6 million, boosted by a $100 million loan from Oxford Finance.
Following the sale of INBRX-101 to Sanofi and subsequent spin-off in May 2024, Inhibrx now focuses on two clinical programs: INBRX-109 and INBRX-106. Key data readouts are expected in 2025, including Phase 2 trial results for INBRX-109 in chondrosarcoma (Q3) and Phase 2 data for INBRX-106 in head and neck cancer (Q4).
Operating expenses decreased significantly, with R&D expenses falling to $36.9 million from $63.9 million, and G&A expenses reducing to $6.0 million from $10.0 million year-over-year.
Inhibrx Biosciences (NASDAQ: INBX) announced key leadership changes as co-founder and CSO Dr. Brendan Eckelman departs to establish a new private biotech company. The company has appointed Dr. Carlos Bais, current Executive VP of Translational Sciences, as the new CSO, and promoted David Matly to President while maintaining his existing roles.
As part of the transition, Inhibrx has entered into an exclusive license agreement with Dr. Eckelman's new venture for certain unused technologies, including provisions for upfront payment and future development milestones. David Matly, who played a important role in Inhibrx's $2.2B asset sale of INBRX-101 to Sanofi in 2024, will oversee clinical development, R&D, technical operations, and regulatory affairs in his expanded role.